1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial. (September 2015) - Sotiriou, C.; Venet, D.; Fumagalli, D.; Maetens, M.; Rothé, F.; Ignatiadis, M.; Bradbury, I.; Harbeck, N.; Gomez, H.; Chang, T.W.; Coccia-Portugal, M.A.; Di Cosimo, S.; et al.